Member Info for Bella6532

Not exactly a big push to get todays news out there in the media...holding back for a reason perhaps? There's definitely more to all this and they aren't showing their hand just yet. CC has been with the company long enough as a Board member to have the inside track and tell us more about the Raise and DX...

Rsm61...just as frustrated as you re the European Healthcare Investor but she won't say anything if they are still negotiating/working on how the company moves forward with this company. Today we had a change of CEO..Step One many on here were wishing for...Step 2 will be fairly soon and pretty significant IMO...

Icecool...I wonder if Avacta have already started working on PreCision warheads for one or more new clients. They have given us details of the areas in which Avacta can be used but not the specific drugs. She did mention somethiing about Immunotherapy towards the end...not sure if I heard her correctly or not though. Could she be talking about using PreCision to carry a patients own Immunotherapy directly into a tumour thus potentially overcoming the lack of 'switch off' which can occur when just pumped into the blood stream.

Cj62...I wouldn't rule out some very interesting updates regarding the company before end Q1...she has to be seen to explain/uncover the real reason behind the 0.50 Placing and what has been decided for DX going forward...once this is done and dusted then the stage will be set for the data release and trial extension etc.

CC closed with...'It has the potential to change the way we treat cancer...'

Other takeaways...

Data already harvested/released HAS unlocked the pipeline and numerous discussions are underway.

Eliot and CC have worked together before.

FAP high or medium doesn't appear to be a big issue...Precision still targets alsmost as if there's no difference.

Much more data being harvested than has been divulged so far.

Much of today's Presentation has already been covered and was going over old ground but some nice little gems in there too.

Roll on Q2

Yes and who might be beefing up the Board...Fund investor(s)...

Now I'm more convinced than ever that we are going to see Levicept Fund Investors coming on board and DX Spun Off.

Are on the move all the time...CC didn't even get a 'wish her all the best' in her last companies new CEO announcement..

Suspect further news updates will be announce under CCs leadership which is effective tomorrow. That way she can kick off with her approach to coms.

AVACTA GROUP PLC - Final Results which will start at 30th Apr 2024 at 12:30pm BST.

Now on the green room you go kitty...

No...all in the name of the WHO a political entity...and look at what they are trying to implement now...

Saint 68...A Spin off is a form of divesting...DX is funded...market can determine valuations of each company...DX and TX function as two separate companies but can have same Board members and same shareholders. If TX goes for a dual listing then DX doesn't have to... There are so many advantages.

Let's see,,,

We have already seen her input...even before this announcement.

Website changes

Videos introduced fronted by her

Presentations made

This is not about AS f***ing up...all the major decisions will have had Board approval and were not done in isolation.

This is about now having a CEO on board with CONTACTS and the first real indication the company now has a focused strategy which has been put in place due to the excellent results seen so far in the AVA6000 trial...Networking, networking, networking...she can talk to the players we now need to be talking to...she brings a much bigger picture to the company especially when it comes to Oncology and the US.

What we don't know is what information/feedback Avacta is getting from our existing Partners. From their comments Point sounds secure after the sales to EL...which was a possible concern our Agreement could have been terminated. We also don't know what discussions have taken place with the FDA and what favourable comments have come to pass there.

This mornings reaction is what often happens once Results are issued...no surprises there.

I still don't understand why it is assumes DX will be sold...as I've said there are other possibilities which might be considered. Why sell off a business which can use our Affimers in their products. TX is going to become an Oncology only business with Precision and Affimers...DX can be Spun Off as a completely separate entity and that can take forward Affimers in DX.

The Board has made the decision to change the CEO and our Board Chairman is EF who has just been made CEO of Levicept which is basically funded and run by 4 major Investment Funds who know their stuff...watch this space...

Could get more RNSs this week under CC watch...she takes over tomorrow...

Not a sudden move...this has been on the cards for a while...

Where is he going?...or will he become CEO of DX...

More changes to come??? Better coms??? 'The Avacta Board of Directors has been preparing for CEO succession, supported by a third-party recruitment specialist. As part of this process, it has considered a wide range of candidates as a potential new CEO for the Group, reviewing both external and internal candidates. Dr. Coughlin emerged from these activities as the outstanding candidate for CEO. The Board also plans a broader evolution in order to meet the increased demands of being a clinical stage oncology company, alongside the need to more clearly communicate with shareholders and other key stakeholders.'

'New leadership and strong clinical momentum positions Avacta well for its evolution into a therapeutics-focused business'

SAYS IT ALL...Spin off diagnostics and bring in Alliance Partner for AVA6000. Who is CC big mates with...keep an eye on X...

Raise at 50p not explained...it's not what they say it's what's not said.

CC takes over tomorrow. These Results are last under AS...

Sll change tomorrow and will move quickly...that's the American no nonsence/slick way...and she had/has a agent???

'As indicated, Avacta plans to focus its resources on its therapeutic programmes and will therefore look to divest the Diagnostics Division in a manner that maximises value for shareholders and the strategic benefits of a focused biotech strategy.'

A Spin-off will happen....

From Feb Fundraise RNS...note very last sentence...'actively'...you have been told...it might not be announced tomorrow but it will be fairly soon...I think...

'The Group continues to explore all available pathways to appropriately finance its clinical therapeutics programmes over the longer term, including non-dilutive funding through business development, attracting global specialist biotech investors and potentially a NASDAQ dual-listing. Avacta is also actively exploring routes to divest its Diagnostics division in a manner which maximises value for shareholders.'

Rambo23...it could happen but that's the risk Avacta take if they choose to demerge DX. However, for every seller there's a buyer.

I certainly wouldn't have a problem with it.